Product
AV7909
Aliases
AV7909 Anthrax Vaccine, AV7909 Formulation 1, AV7909 Formulation 2, AV7909 Formulation 3 (2 other aliases)
6 clinical trials
3 indications
Indication
AnthraxIndication
Anthrax InfectionIndication
Anthrax VaccineClinical trial
A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy AdultsStatus: Completed, Estimated PCD: 2020-08-06
Clinical trial
A Parallel-arm, Double-blind, Randomized, Placebo-controlled, Dose-ranging Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of AV7909 in Healthy AdultsStatus: Completed, Estimated PCD: 2012-05-01
Clinical trial
A Phase 2, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Evaluate the Safety and Immunogenicity of AV7909 for Post-Exposure Prophylaxis of Anthrax Using Three Immunization Schedules and Two Dose Levels in Healthy Adult VolunteersStatus: Completed, Estimated PCD: 2014-02-01
Clinical trial
A Phase 2 Drug-Vaccine Interaction Study to Examine Whether Co-administering AV7909 With Ciprofloxacin or Doxycycline Affects Antibiotic Pharmacokinetics or AV7909 Immunogenicity in Healthy AdultsStatus: Completed, Estimated PCD: 2020-03-05
Clinical trial
A Randomized, Double-blinded, Multicenter Study in Healthy Adults to Evaluate Safety and Immunogenicity of AV7909 Administered at Two Dose Levels on Two Vaccination Schedules, Including a Primary Series and Booster DosesStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1, Randomized, Parallel-Group, Double-Blind Trial of AV7909 (Liquid) and Thermostable AV7909 (Lyophilized) in Healthy Adult VolunteersStatus: Completed, Estimated PCD: 2023-11-01